Grandfield & Dodd LLC Grows Stock Position in Exact Sciences Corporation $EXAS

Grandfield & Dodd LLC lifted its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 3.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 116,547 shares of the medical research company’s stock after buying an additional 3,787 shares during the quarter. Grandfield & Dodd LLC owned approximately 0.06% of Exact Sciences worth $6,193,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of EXAS. Allworth Financial LP grew its stake in shares of Exact Sciences by 14.3% during the 1st quarter. Allworth Financial LP now owns 2,986 shares of the medical research company’s stock worth $136,000 after purchasing an additional 373 shares during the period. Cerity Partners LLC boosted its holdings in Exact Sciences by 24.0% during the first quarter. Cerity Partners LLC now owns 33,598 shares of the medical research company’s stock worth $1,454,000 after buying an additional 6,508 shares in the last quarter. CWM LLC grew its position in Exact Sciences by 41.2% during the first quarter. CWM LLC now owns 21,316 shares of the medical research company’s stock valued at $923,000 after buying an additional 6,217 shares during the period. Larson Financial Group LLC increased its holdings in Exact Sciences by 2,804.8% in the first quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock valued at $26,000 after buying an additional 589 shares in the last quarter. Finally, Private Advisor Group LLC raised its position in shares of Exact Sciences by 39.2% in the first quarter. Private Advisor Group LLC now owns 31,742 shares of the medical research company’s stock worth $1,374,000 after acquiring an additional 8,946 shares during the period. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on EXAS. Guggenheim raised their target price on Exact Sciences from $70.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. TD Cowen increased their price target on Exact Sciences from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Zacks Research upgraded Exact Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada decreased their target price on Exact Sciences from $54.00 to $46.00 and set a “sector perform” rating on the stock in a research report on Thursday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $74.06.

Exact Sciences Price Performance

Exact Sciences stock opened at $67.75 on Friday. The company has a fifty day simple moving average of $59.57 and a 200-day simple moving average of $54.03. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $12.84 billion, a price-to-earnings ratio of -12.48, a PEG ratio of 5.56 and a beta of 1.34. Exact Sciences Corporation has a 52-week low of $38.81 and a 52-week high of $72.81.

Exact Sciences (NASDAQ:EXAS) last issued its earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.11. The business had revenue of $850.74 million during the quarter, compared to the consensus estimate of $810.42 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The company’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same period last year, the company earned ($0.21) EPS. Exact Sciences has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Insider Buying and Selling at Exact Sciences

In other news, EVP Brian Baranick sold 2,858 shares of Exact Sciences stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $70.08, for a total value of $200,288.64. Following the completion of the sale, the executive vice president directly owned 22,368 shares of the company’s stock, valued at approximately $1,567,549.44. The trade was a 11.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director James Edward Doyle sold 2,000 shares of the business’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $60.00, for a total transaction of $120,000.00. Following the sale, the director owned 57,962 shares in the company, valued at $3,477,720. This trade represents a 3.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 1.20% of the company’s stock.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.